Effect of Octreotide on prophylaxis of post ERCP pancreatitis and hyperamylasemia: a multicenter, randomized clinical trial
- VernacularTitle:奥曲肽预防ERCP术后胰腺炎及高淀粉酶血症的多中心随机对照临床研究
- Author:
Zhaoshen LI
;
Wenjun ZHANG
;
Xue PAN
- Publication Type:Journal Article
- Keywords:
Octreotide;
Endoscopic retrograde cholangiopancreatograph;
Pancreatitis;
Hy-peramylasemia;
Prevention
- From:
Chinese Journal of Digestive Endoscopy
1996;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study on the efficacy of Octreotide prophylaxis of post ERCP pancreatitis (PEP) and hyperamylasemia. Methods The study was conducted in 12 digestive endoscopic units in China. Patients were randomized into two groups. Octreotide group: Octreotide (0. 3mg) were dissolved in 500 ml of 0.9% saline solution and administrated by continues intravenous infusion, beginning 1 hr before the endoscopic examination and continuing for 6 hr afterward, 0. 1 mg Octreotide were injected subcutaneously at 6h, 12h after the intravenous injection stopped. Control group was given a placebo (saline solution) intravenously without subcutaneous injection. Results A total of 961 patients were accepted in the study, 832 patients were enrolled in the final analysis, Octreotide group 414 cases, and control group 418 cases. The overall incidence of acute pancreatitis was 3.85% (32/832) .which includec 2.42% (10/414) in Octreotide group and 5. 26% (22/418) in control group (P =0. 046). Incidence of hyperamylasemia was 14. 9% (124/ 832) which included 12. 32% (51/414) in Octreotide group and 17. 46% (73/418) in controlled group (P = 0. 041). The two groups were matched in many basic aspects, such as sex, age, contrast agent, indication of ERCP, the times of visualization of pancreatic duct and bile duct, etc. There was no side effect associated with Octreotide found. Conclusion The results of this trial indicate that Octreotide can prevent post ERCP pancreatitis and hyperamylasemia.
